Cohort Studymoderate evidence

Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study.

Molecular psychiatry·December 1, 2025·PMID 40931165

Why it matters

GLP-1/GIP receptor agonists are widely used for diabetes and obesity, but their potential in addiction medicine is underexplored. This genetic evidence suggests these drugs may reduce harmful drinking, offering a novel therapeutic avenue for alcohol use disorders.

Infographic summary of Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled